Aflibercept for Diabetic Macular Edema In Real-life Practice in GREece

University of Athens100 enrolled

Overview

ADMIRE was a prospective, observational cohort study of patients with diabetic macular edema (DME). Efficacy was assessed by change in best-corrected visual acuity (BCVA) and central retinal thickness (CRT) from baseline to months 12, 24 and 36 after treatment with intravitreal aflibercept in treatment-naïve patients and previously treated patients. Safety was evaluated by recording any patients-reported events.

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Diabetic Macular Edema

Interventions

AfliberceptDRUG

Intravitreal aflibercept as used in the routice clinical practice

Eligibility

Sex: ALLMin age: 45 Years

Medical Language ↔ Plain English

Inclusion Criteria: Patients with DM, able to give written informed consent Patients with DME\>320 μm, who need treatment Exclusion Criteria: Patients with other retinal diseases than DME Intraocular surgery within the last 6 months

Locations (1)

University of Athens

Athens, Greece

Outcomes

Primary Outcomes

Change in best-corrected visual acuity

Time frame: 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.